# Treatments Against RA and Effect on FDG-PET/CT

> **NCT02374021** · PHASE4 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 159 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Sulfasalazine
- **DRUG:** Hydroxychloroquine
- **DRUG:** Etanercept
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT02374021
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2021-05
- **Final completion:** 2021-05
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2022-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02374021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02374021, "Treatments Against RA and Effect on FDG-PET/CT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02374021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*